Intuitive Surgical, Inc. $ISRG Shares Bought by IFM Investors Pty Ltd

Key Points

• IFM Investors Pty Ltd increased its stake in Intuitive Surgical by 5.6%, owning 72,714 shares valued at approximately $39.5 million as of the latest SEC disclosure.
• Insider sales included 29,360 shares sold by CEO Gary S. Guthart, significantly reducing his position by 59.69%.
• Analyst ratings for Intuitive Surgical vary, with opinions ranging from a "sell" to a "buy," and a consensus target price of $595.95.

IFM Investors Pty Ltd raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 5.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 72,714 shares of the medical equipment provider's stock after purchasing an additional 3,832 shares during the period. IFM Investors Pty Ltd's holdings in Intuitive Surgical were worth $39,514,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Chilton Capital Management LLC boosted its stake in shares of Intuitive Surgical by 614.3% during the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 43 shares during the last quarter. Global Financial Private Client LLC boosted its stake in shares of Intuitive Surgical by 253.3% during the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock valued at $26,000 after acquiring an additional 38 shares during the last quarter. Elite Financial Inc. acquired a new stake in shares of Intuitive Surgical during the first quarter valued at $26,000. LFA Lugano Financial Advisors SA acquired a new stake in shares of Intuitive Surgical during the first quarter valued at $30,000. Finally, TD Capital Management LLC boosted its stake in shares of Intuitive Surgical by 300.0% during the first quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock valued at $30,000 after acquiring an additional 45 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company's stock.

Insider Activity

In other news, insider Gary S. Guthart sold 29,360 shares of the company's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $472.49, for a total transaction of $13,872,306.40. Following the completion of the sale, the insider owned 19,827 shares in the company, valued at approximately $9,368,059.23. This represents a 59.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Myriam Curet sold 4,500 shares of the business's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the transaction, the executive vice president directly owned 353 shares of the company's stock, valued at $173,845.44. This represents a 92.73% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 45,224 shares of company stock worth $21,716,492. 0.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ISRG shares. Deutsche Bank Aktiengesellschaft reiterated a "sell" rating on shares of Intuitive Surgical in a research report on Friday, August 22nd. UBS Group increased their target price on Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Royal Bank Of Canada reiterated an "outperform" rating and set a $615.00 target price on shares of Intuitive Surgical in a research report on Tuesday, August 19th. Citigroup reiterated a "buy" rating and set a $650.00 target price (up from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Finally, Zacks Research downgraded Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. Thirteen research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $595.95.

Intuitive Surgical Trading Up 0.5%

NASDAQ ISRG opened at $435.83 on Friday. The stock's 50-day moving average price is $478.10 and its two-hundred day moving average price is $504.94. The company has a market cap of $156.24 billion, a PE ratio of 60.79, a PEG ratio of 4.55 and a beta of 1.61. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.93 by $0.26. The firm had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The business's revenue for the quarter was up 21.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.78 EPS. Research analysts forecast that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.